A stabilised hypochlorous solution is disclosed. The solution includes hypochlorous acid (HOCl), hypochlorite (ClO—), and chlorine (Cl—) that combine to provide a total chlorine concentration. The total chlorine concentration is at or below 300 ppm, the hypochlorous acid, measured by UV spectroscopy at 230 nm, is the predominant species, the hypochlorite, measured by UV spectroscopy at 290 nm, is present at significantly lower levels than that of the hypochlorous acid, such that a ratio of hypochlorous acid to hypochlorite is greater than 7.5:1. The solution has a pH of between about 7 and 4 and a shelf life of at least 12 months, at 22° C., such that the amount of hypochlorous present remains at above 80% of its starting concentration, and the pH remains above 4.

A stabilised hypochlorous solution is disclosed. The solution includes hypochlorous acid (HOCl), hypochlorite (ClO—), and chlorine (Cl—) that combine to provide a total chlorine concentration. The total chlorine concentration is at or below 300 ppm, the hypochlorous acid, measured by UV spectroscopy at 230 nm, is the predominant species, the hypochlorite, measured by UV spectroscopy at 290 nm, is present at significantly lower levels than that of the hypochlorous acid, such that a ratio of hypochlorous acid to hypochlorite is greater than 7.5:1. The solution has a pH of between about 7 and 4 and a shelf life of at least 12 months, at 22° C., such that the amount of hypochlorous present remains at above 80% of its starting concentration, and the pH remains above 4.

The present invention relates to a pharmaceutical composition of chlorine for treatment of respiratory viral infection. More particularly, the invention relates to the pharmaceutical composition of chlorine administered by inhalation for the treatment of viral infection associated with COVID and viral morbidities.

The present invention is directed to methods for treating or ameliorating skin conditions, diabetic conditions, cardiovascular conditions, cancer, infections or metal poisoning, enhancing performance, or providing nutritional support, comprising administering to a subject in need thereof compositions comprising a magnetic dipole stabilized solution (MDSS). The MDSS solution may include additional components and can be provided in a kit.

The present invention is directed to methods for treating or ameliorating skin conditions, diabetic conditions, cardiovascular conditions, cancer, infections or metal poisoning, enhancing performance, or providing nutritional support, comprising administering to a subject in need thereof compositions comprising a magnetic dipole stabilized solution (MDSS). The MDSS solution may include additional components and can be provided in a kit.

Provided herein are dynamic clusters of atom particles activated in extracellular fluid intended to reverse the accumulation of advanced glycation end products which are closely related to chronic diseases. The manufacturing process involves material preparation, particle fragmentation, pH adjustment, selection of atom particles and construction of dynamic clusters through electro-magnetic field and flow velocity adjustment, and separation of dynamic clusters from the liquid. The dynamic clusters of atom particles deal with advanced glycation end products, which are diverse in chemical nature, by responding to irregularities in the electromagnetic field disrupted by highly reactive free radicals advanced glycation end products emit. Such mechanism makes it possible to extend the applications to diseases related to irregular free radical activities other than chronic diseases like in HIV replication or neural signalling.

Provided herein are dynamic clusters of atom particles activated in extracellular fluid intended to reverse the accumulation of advanced glycation end products which are closely related to chronic diseases. The manufacturing process involves material preparation, particle fragmentation, pH adjustment, selection of atom particles and construction of dynamic clusters through electro-magnetic field and flow velocity adjustment, and separation of dynamic clusters from the liquid. The dynamic clusters of atom particles deal with advanced glycation end products, which are diverse in chemical nature, by responding to irregularities in the electromagnetic field disrupted by highly reactive free radicals advanced glycation end products emit. Such mechanism makes it possible to extend the applications to diseases related to irregular free radical activities other than chronic diseases like in HIV replication or neural signalling.

Topical compositions for skin include an active substance and a cell penetrating peptide consisting of following sequence: NYBX1BX2BNQX3. The cell penetrating peptide is not only capable of delivering the active substance into skin cells effectively but also promoting the activity of the active substance.

Topical compositions for skin include an active substance and a cell penetrating peptide consisting of following sequence: NYBX1BX2BNQX3. The cell penetrating peptide is not only capable of delivering the active substance into skin cells effectively but also promoting the activity of the active substance.

A method of neutralizing adverse biological effects of Interleukin 6 (IL-6) and other pro-inflammatory Interleukins in vivo is disclosed using homogeneous solutions of hypohalous acids to modify binding sites on cytokines and chemokines that are responsible for activation of cell surface receptors, and the initiation of harmful inflammatory processes or the growth of cytokine-dependent malignancies or of malignancies dependent on other chemical growth factors.